The role of the renin-angiotensin system in the pathophysiology, prevention, and treatment of renal impairment in patients with the cardiometabolic syndrome or its components

Journal of the CardioMetabolic Syndrome

Volumn 4, Issue 1, 2009, Pages 57-62

  Alpert, Martin A ^a,b,c   Govindarajan, Gurushankar ^a,b   Del Rosario, Marc L E ^a,b   Reisin, Efrain ^a,b  

^a University of Missouri   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GROWTH FACTOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG TARGETING; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; UPREGULATION; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; HUMANS; METABOLIC SYNDROME X; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 61349089320     PISSN: 15594564     EISSN: 15594572     Source Type: Journal    
DOI: 10.1111/j.1559-4572.2008.00035.x     Document Type: Review

References (46)

1. U.S. Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
2. Centers for Disease Control and Prevention: Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007;56:161-165.
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
4. Guidelines Subcommittee. World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens. 1999;17:151-183.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): Final report. Circulation. 2002;106:3143-3421.
6. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
7. Alberti KG, Zimmer PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part I: Diagnosis and classification of diabetes mellitus provisional report of WHO consultation. Diabet Med. 1998;15:539-553.
8. Cheung BMY, Ong KL, Man YB, et al. Prevalence of the metabolic syndrome in the United States National Health and Nutrition Examination Survey 1999-2002 according to different defining criteria. J Clin Hypertens (Greenwich). 2006;8:562-570.
9. Alberti KG, Zimmer PZ, Shaw J, et al. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-1062.
10. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109:42-46.
11. Lakka H-M, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
12. Laaksonen DE, Lakka H-M, Niskanen LK, et al. Metabloic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070-1077.
13. Wilson PWF, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-3072.
14. Hanson RL, Imperatore G, Bennett PH, et al. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes. 2002;51:3120-3127.
15. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134-2140.
16. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167-174.
17. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16:952-958.
18. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:550-562.
19. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: Role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35:807-825.
20. Engeli S, Böhnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356-362.
21. Hall JE, Brands MW, Zappe DH, et al. Hemodynamic and renal responses to chronic hyperinsulinemia in obese, insulin-resistant dogs. Hypertension. 1995;25:994-1002.
22. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;2:625-633.
23. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: Mechanisms and implications. Am J Nephrol. 2006;26:232-244.
24. Remuzzi G, Perico N, Macia M, et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005;68(suppl 99):S57-S65.
25. Raij L. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am J Hypertens. 2005;18:95S-99S.
26. Kopyt NP. Slowing progression along the renal disease continuum. J Am Osteopath Assoc. 2005;105:207-215.
27. Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351-1356.
28. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.
29. Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med. 2006;119(suppl 5A):40S-47S.
30. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
31. Zandbergen AAM, Baggen MGA, Lamberts SWJ, et al. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. Ann Intern Med. 2003;139:90-96.
32. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation. 2002;106:672-678.
33. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
34. Parving H-H, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
35. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
36. Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:1921-1926.
37. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577-1578.
38. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;12:2735-2752.
39. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care. 2006;29(suppl 1):S4-S42.
40. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(suppl 2):S1-S180.
41. Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(suppl 2):B54-B64.
42. Estacio RO, Coll JR, Tran ZV, et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens. 2006;19:1241-1248.
43. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719-2728.
44. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
45. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes. The candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
46. Persson F, Rossing P, Schioedt US, et al. Time course of the antiproteinuric and antihypersensitive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73:1419-1425.